Stimulants
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Stimulants
Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
On-Demand Session
Overview
According to the CDC, from 2012 through 2020 in the United States, the number of deaths involving methamphetamine increased more than 6-fold while the number of deaths involving cocaine more than tripled. This session will focus on the prevention and treatment of stimulant use disorders and will discuss topics such as new clinical practice guidelines, novel pharmacotherapies, methamphetamine-induced psychotic disorders, and more.
This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.
- Novel Approaches to the Prevention and Treatment of Stimulant Use Disorders
This presentation will summarize prevention and treatment recommendations from the new ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. Key takeaways from the guideline will be discussed. Topics for discussion will include behavioral and pharmacological treatments, co-occurring conditions, management of stimulant intoxication and withdrawal, and secondary and tertiary prevention strategies to reduce harms associated with risky stimulant use. - Mosaic Approaches to Understanding ADHD and Stimulant Use Disorders
This session provides an overview of ADHD, including diagnostic criteria and key characteristics, with a focus on understanding the overlap between ADHD and substance use disorders. Participants will explore methods to reduce stimulant misuse and examine the trajectories of substance use disorders in individuals with ADHD. The discussion will also highlight how the COVID-19 pandemic shifted diversion sources among adolescents and young adults, emphasizing the evolving nature of these challenges. - BEAT Meth: New Findings for Advancing Methamphetamine Addiction Treatment
The pathophysiology of methamphetamine addiction--including its intense biological reinforcement and symptom profile--poses challenges for prevention and treatment. Attendees will hear original findings from BEAT Meth, a CDC-funded project that applies a multifaceted public health approach to addressing methamphetamine addiction. These findings include strategies to describe methamphetamine-related healthcare utilization; diagnostic criteria for methamphetamine-induced psychotic disorders; and adaptation of contingency management to support linkage to care. - Development of Dual-Acting Sigma and Dopamine Transporter Inhibitors as Potential Pharmacotherapy for Stimulant Use Disorders
This session will describe a novel pharmacotherapy mechanism of treating stimulant use disorder. The attendees will be able to explain the necessity for the dual mechanism of action in the drugs ability to attenuate rodents from self-administering cocaine. This session will also demonstrate the success of this concept, the challenges that are still ahead with drug development, and the potential for this treatment to be game changing as an aid in the treatment of stimulant use disorders.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
DEA Education Requirement
As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Open: 11/01/2024 - 10/01/2027
User Access Closed: 11/01/2027
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Note for pharmacists: Not all courses offer CPE Credit. For courses that do offer CPE Credit, pharmacists must claim credit and provide their eProfile ID and Birthdate via the Pharmacist Survey within 30 days of completing the activity. ASAM will not report CPE Credits claimed 30+ days after activity completion to ACPE. ASAM will not report CPE Credits without accurate and complete information. Courses offering CPE Credit will indicate the amount of credit available for pharmacists on the Credits & Disclosure Tab. For any questions or concerns, please e-mail Education@ASAM.org
Brian Hurley
MD, MBA, DFASAM
Brian Hurley, MD, MBA, DFASAM is an addiction physician and the Director of Addiction Medicine for the Los Angeles County Department of Health Services. Brian is currently a Director at Large for the American Society of Addiction Medicine (ASAM) and will assume the position of President-Elect this April 2021. He co-chairs the Los Angeles County Department of Health Services’ Substance Use Disorders Workgroup and the SafeMedLA Medications for Addiction Treatment Action Team, and is the Clinical Director of the Addiction Treatment Starts Here programs through the Center for Care Innovations, focused on increasing the delivery of Medications for Addiction Treatment in California’s community health centers. He is the PI of two MAT Access Points projects funded by the Sierra Health Foundation, a co-PI of a TRDRP funded smoking cessation implementation project, and a co-investigator on NIDA, NIAAA, and PCORI funded addiction related implementation science grants managed through RAND. He is a member of the Motivational Interviewing Network of Trainers and regularly conducts motivational interviewing trainings throughout the United States. He is a Volunteer Assistant Clinical Professor of Addiction Medicine in the Department of Family Medicine at the UCLA David Geffen School of Medicine. He additionally serves on the American Board of Psychiatry and Neurology’s Addiction Psychiatry examination writing committee.
Brian completed the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles (UCLA), and was previously a UCLA - Veterans Administration National Quality Scholar at the VA Greater Los Angeles Healthcare System. He completed a fellowship program in addiction psychiatry at New York University School of Medicine. He completed residency training at the Massachusetts General Hospital and McLean Hospital, where he was Chief Resident in Addiction Psychiatry. Brian is a former National President of the American Medical Student Association.
No relevant financial disclosures
Vita V. McCabe, MD, MHSA, FACS, FCCP, FASAM
Addiction Psychiatrist
University of Michigan, Ann Arbor
Dr. McCabe is a University of Chicago Medical School alumna and former cardiothoracic surgeon. She shifted her career focus after retiring due to physical health issues in 2015.
With a master’s in health management and policy from the University of Michigan School of Public Health, her expertise now spans physician systems change, impairment and resilience and is deeply influenced by her own personal journey with physical disability that affected her career as a surgeon and her family’s history of addiction.
Dr. McCabe has made notable and significant contributions, including serving on the Illinois State Medical Board’s Impairment Council and chairing the Michigan’s Health Provider Assistance Committee which is the oversight body for the Health Professionals Recovery Program for 25 health professional boards. Her work has impacted policies on stimulants for the FDA and support systems for impaired physicians across six hospitals and within a national healthcare system. She has over 50 peer reviewed publications and her current research efforts focus on trajectories of SUD and ADHD.
Dr. McCabe embraced her passion for mental health, completing her psychiatry residency and addiction psychiatry fellowship at the University of Michigan
where she is a clinical associate professor of addiction psychiatry and is also boarded in addiction medicine.
No relevant financial disclosures
.jpg "Speaker image")
Alia Al-Tayyib, PhD
Associate Research Scientist
Denver Health
Alia Al-Tayyib, PhD, MSPH, is an Associate Research Scientist at the Public Health Institute at Denver Health and an Associate Professor in the Department of Epidemiology at the Colorado School of Public Health. Dr. Al-Tayyib's primary research interests are in behavioral risks for acquiring and transmitting infections, such as HIV and hepatitis C, with a focus on the social and structural determinants of risk. Since 2007, she has served as the site PI for the National HIV Behavioral Surveillance (NHBS) system in the Denver metro area. More recently, Dr. Al-Tayyib has focused on social network studies examining the transition from oral ingestion of prescription opioids to injection drug use among at-risk youth and on developing interventions to keep people engaged in care for substance use disorders. The overarching goal of her work is to reduce the spread of infections, decrease substance use, and improve public health. Dr. Al-Tayyib currently leads the research efforts for the Denver Health Center for Addiction Medicine. She received her PhD and MSPH degrees in Epidemiology from the University of North Carolina at Chapel Hill and is an alumna of the Clinical Faculty Scholar and the Leadership for Innovative Team Science programs at the Colorado Clinical and Translational Sciences Institute.
Christopher R. McCurdy, BSPh, PhD, FAAPS
Professor
University of Florida
Dr. McCurdy serves as Associate Dean for Faculty Development and Professor in the Departments of Medicinal Chemistry and Pharmaceutics; and The Frank A. Duckworth Eminent Scholar Chair in Drug Research and Development at the University of Florida College of Pharmacy. He is also the Director of the UF Translational Drug Development Core. Dr. McCurdy completed his training as a pharmacist at Ohio Northern University and moved on to complete his PhD in medicinal chemistry from the University of Georgia, followed by a three-year postdoctoral fellowship at the University of Minnesota under Prof Philip Portoghese. McCurdy began his academic career in 2001 at the University of Mississippi where he rose to the rank of full professor (with tenure). He moved to the University of Florida in January of 2017. His research focuses on the design, synthesis, and development of drugs to treat pain, anxiety, and substance use disorders. He is an internationally recognized expert on kratom (Mitragyna speciosa). He also has developed a PET/MR imaging diagnostic agent for visualizing the origins of chronic neuropathic pain. Phase 1 and 2 human clinical trials are currently underway. He has published more than 200 manuscripts and holds 8 patents. He is currently funded by multiple NIH grants and the Florida Department of Health. Dr. McCurdy serves as a consultant to the US Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee and previously served as President of the American Association of Pharmaceutical Scientists (AAPS).
No relevant financial disclosures
Credits & Disclosures
Joint Accreditation Statement
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available
- Physicians: 2 Credit(s)
- Nurses & NPs: 2 Nursing Contact Hour(s)
- Pharmacology Hour(s): 1.75 Hour(s)
- PAs: 2 Credit(s)
- Pharmacists: 2 Credit(s)
- Interprofessional Continuing Education: 2 Credit(s)
- Certified Counselors: NBCC Contact Hours Not offered
Note for pharmacists: Not all courses offer CPE Credit. For courses that do offer CPE Credit, pharmacists must claim credit and provide their eProfile ID and Birthdate via the Pharmacist Survey within 30 days of completing the activity. ASAM will not report CPE Credits claimed 30+ days after activity completion to ACPE. ASAM will not report CPE Credits without accurate and complete information. Courses offering CPE Credit will indicate the amount of credit available for pharmacists on the Credits & Disclosure Tab. For any questions or concerns, please e-mail Education@ASAM.org
Maintenance of Certification (MOC)/Continuing Certification Program (CCP)
This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.
- ABA MOCA 2.0®*: 2 Lifelong Learning
- ABIM MOC Points: 2 Medical Knowledge
- ABP MOC: 2 Lifelong Learning & Self-Assessment
- ABS Continuing Certification: 2 Accredited CME | 2 Self-Assessment
Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.
- American Board of Addiction Medicine (ABAM)
- American Board of Preventative Medicine (ABPM)
- American Board of Psychiatry and Neurology (ABPN)
- Royal College of Physicians and Surgeons of Canada (RCPSC)
Certificates for other professions
All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1225.
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205.
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1224.
MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.
Disclosure Information
In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.
See the attached pdf for a list of disclosures.
Key:
Complete
Next
Failed
Available
Locked